# Book Loss Huge, Cash Flow Steady! Did Fosun Make the Right Move?

Why does Fosun International remain financially stable despite massive losses?

Produced by | China Visitor Network

Reviewed by | Li Xiaoyan

On March 6, Fosun International issued a profit warning, estimating a net loss attributable to shareholders of 21.5 to 23.5 billion yuan in 2025, nearly four times the loss in 2024, which drew significant market attention. From the data, this loss has wiped out the accumulated profits of the past five years, creating a strong shock to numbers; but upon deeper analysis, this is not an operational collapse, rather a strategic choice by Fosun to cut water, clear risks, and streamline operations—an essential pain point in the company’s cycle of returning to its core business. Management has set a goal to reach hundreds of millions in profit within three to five years, which is not an empty dream but a rational outlook based on asset disposals, structural optimization, and strengthening core businesses. This is a clear reversal of the predicament through a “retreat to advance” strategy.

The core reason for this massive loss is a one-time non-cash asset impairment, not a cash flow break or collapse of main operations. Fosun International explicitly states in its announcement that the loss mainly stems from two aspects: first, ongoing downturn in the real estate sector leading to large asset impairments on some property projects; second, revaluation and impairment of goodwill and intangible assets in non-core businesses. Both actions follow prudent accounting principles, objectively adjusting the value of historical assets, without actual cash outflows or impact on daily operations and cash flow. In the first half of 2025, the company still achieved a net profit attributable to shareholders of 660 million yuan, with operating cash flow reaching 14.605 billion yuan, up 37.15% year-over-year. This solid cash flow foundation provides strong support for the company’s transformation.

Reviewing Fosun’s development history, the company initially relied on real estate and pharmaceuticals, building a diversified industrial landscape through global acquisitions. While this expansion brought scale growth, it also planted hidden risks of low profitability and high debt pressure. From 2010 to 2024, net assets increased from 45 billion to 197.5 billion yuan, but return on net assets fluctuated downward; interest-bearing debt rose from 43.9 billion to 222.1 billion yuan, pushing up financial costs. From 2022 to 2024, annual net interest expenses exceeded 10 billion yuan, creating a cycle of rising debt, high costs, and profit pressure. Additionally, accumulated goodwill from long-term acquisitions remained high, reaching 29.548 billion yuan at the end of 2023, while cumulative impairments over the past decade were only 938 million yuan, causing a gradual divergence between asset value and actual market performance.

Early on, Fosun recognized the risks of “virtual fat,” and in 2018 proposed a shift to light assets. In 2022, it officially launched a “slimming and strengthening” strategy, shifting from “buying” to “selling,” actively divesting non-core assets. From 2022 to 2024, the company exited about 75 billion yuan of non-core assets, and in the first half of 2025, continued to dispose of over 10 billion yuan, continuously optimizing its debt ratio. The recent large impairments are a key step in this strategy: impairing real estate assets in line with market conditions to reflect true value during industry downturns; consolidating the disposal of non-core goodwill to cut burdens from inefficient assets. This is an inevitable move in the “big ship turn-around,” using a one-time financial “spring cleaning” to remove excess assets, strengthen the financial base, and clear obstacles for future lean operations.

Objectively, challenges remain in the transformation process: after impairments, related assets still carry high book values, and the pace of disposals and asset quality need ongoing monitoring; some business segments are affected by industry cycles, with profits in “happy” and “intelligent manufacturing” sectors declining in the first half of 2025, and recovery in consumer and manufacturing sectors still requiring time; high debt pressure has not been fully alleviated, with short-term interest-bearing liabilities exceeding cash reserves, and interest expenses continuing to erode profits. Rising asset mortgage ratios also constrain financing flexibility. These issues are common in diversified giants’ transformation and are ongoing challenges Fosun must address.

However, under these challenges, the resilience and growth potential of core businesses are the strongest confidence for Fosun’s turnaround. The company remains committed to the four major sectors: “health, wealth, happiness, and intelligent manufacturing,” focusing resources on pharmaceutical innovation, insurance finance, and cultural tourism with light assets, gradually releasing industry synergy. The pharmaceutical sector, as a core engine, has achieved significant results in innovative drug R&D and commercialization, with several products licensed overseas, opening long-term growth space through global expansion; the wealth sector, relying on insurance, has become a stable “cash cow,” with premium income and net profit both growing, providing continuous cash flow; cultural tourism and high-end consumer businesses leverage brand advantages, gradually emerging from industry lows, with operational efficiency steadily improving.

Following the loss announcement, Fosun International quickly signaled positivity: management held a conference call to clarify strategic direction, and the controlling shareholder and management announced plans to increase holdings by no more than 500 million HKD within 12 months, demonstrating confidence in the company’s future. From an operational perspective, this “big cleanup” significantly reduces future impairment pressure, providing more flexibility in profit statements; asset disposals and debt optimization are progressing simultaneously, with debt structure continuously improving and financing costs expected to decline gradually; core business shifting from “scale expansion” to “quality improvement,” with endogenous growth drivers strengthening, laying a solid foundation for the hundred-billion profit goal.

For large diversified industrial groups, cyclical fluctuations and strategic adjustments are normal parts of growth. Fosun’s massive loss this time is a rational correction of past expansion models and a bold move to respond to industry cycles and resolve historical burdens. Short-term accounting losses have paved the way for long-term asset quality improvement, clearer focus on core businesses, and a reconstruction of growth momentum. Moving from reckless expansion to active slimming, from scale-first to quality-first, Fosun is undergoing a profound strategic transformation.

In the future, as non-core assets continue to be divested, debt structures are optimized, and core businesses are enhanced, Fosun is expected to fully emerge from the pain of transformation. This short-term loss-for-long-term health shift is not the end but the beginning of a new journey. Driven by industrial operations and capital management, leveraging core advantages in pharmaceutical innovation and insurance finance, Fosun is poised for steady recovery, aiming to achieve its long-term goal of hundreds of billions in profit and reestablishing the value and vitality of a private industry giant.